Lv5
1438 积分 2024-06-07 加入
A longitudinal atlas of human psoriatic skin reveals the mechanisms of anti-IL-23 therapy in disrupting the type 17 inflammatory circuit
7天前
已完结
A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis
15天前
已完结
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
24天前
已完结
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
24天前
已完结
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
24天前
已完结
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
24天前
已完结
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
1个月前
已完结
Management of the Impact of Psoriasis on Sexuality: Consensus Recommendations From the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology
2个月前
已关闭
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
3个月前
已完结
Disease modification in psoriasis through early interleukin 17 inhibitor intervention: A retrospective cohort study
4个月前
已完结
皖公网安备34019202002308
